Bankers and underwriters have plenty to be thankful for. Bond issuance is running hot, this year’s IPO count is up (at least ...
Pharmaceutical Technology on MSN
Alkermes prevails over Lundbeck in Avadel bidding war
Alkermes will likely proceed with its planned acquisition of Avadel, which experienced an unexpected hitch following Lundbeck ...
Shortly after Alkermes and Avadel announced their deal, Lundbeck made an unsolicited offer of $23 per share, including $21 ...
Within five business days, Alkermes can negotiate with Avadel to amend its original takeover offer to beat Lundbeck.
Merck has made a $9.2 billion play for Cidara, and there’s another bidding war afoot, this one for sleep biotech Avadel. Meanwhile, Rick Pazdur has taken the helm at CDER while tensions run high ...
Jefferies London Healthcare Conference 2025 November 19, 2025 4:00 AM ESTCompany ParticipantsDavid Denton - Executive VP ...
InvestorsHub on MSN
Pfizer aims to seek oral obesity treatments worldwide following Metsera purchase – CEO
Pfizer Inc (NYSE:PFE) is preparing to broaden its presence in the global obesity market, with a particular emphasis on ...
Investing.com -- Pfizer Inc plans to expand its obesity portfolio globally with a focus on oral medications following its Metsera acquisition, Chief Financial Officer Dave Denton said at the Jefferies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback